Target intelligence / Profile preview

2'-Deoxynucleoside 5'-phosphate N-hydrolase 1 (DNPH1)

Target
DNPH1
Molecular classification
Enzyme
01

Overview

2'-Deoxynucleoside 5'-phosphate N-hydrolase 1 (DNPH1) is an enzyme that catalyzes the hydrolysis of the N-glycosidic bond of 5-hydroxymethyl-2'-deoxyuridine 5'-monophosphate (5hmdUMP), producing 2-deoxyribose 5-phosphate and 5-hydroxymethyluracil[1][4]. This reaction is a critical step in a nucleotide salvage pathway that eliminates cytotoxic epigenetically modified nucleotides and prevents their aberrant incorporation into DNA. DNPH1 activity is c-Myc responsive and may be involved in cellular proliferation, differentiation, and apoptosis pathways[3]. Overexpression of DNPH1 in cancer cells leads to resistance to poly(ADP-ribose) polymerase inhibitors (PARPi), and inhibition of DNPH1 can enhance sensitivity to these anticancer agents, making DNPH1 an attractive therapeutic target in oncology[1][5]. Its molecular family is distinct from nucleoside 2'-deoxyribosyltransferases, sharing structural and mechanistic features that rely on a catalytic glutamate residue in covalent catalysis[1].

Other names
5-hydroxymethyl-dUMP N-hydrolaseC6orf108RCLrcldJ330M21.3c-Myc-responsive protein RCLdeoxyribonucleoside 5'-monophosphate N-glycosidase
02

Mechanism of action

DNPH1 inhibition leads to increased accumulation of 5-hydroxymethyl-dUMP in DNA, promoting PARP trapping in cancer cells and resensitizing them to PARP inhibitors[1][5]

03

Biological functions

N-ribosidic bond hydrolysis of 5-hydroxymethyl-2'-deoxyuridine 5'-monophosphateDeoxyribonucleoside monophosphate catabolic processNucleotide salvage pathwayRegulation of cell proliferation (via c-Myc responsiveness)
04

Disease associations

Cancer (notably, PARP inhibitor resistance in BRCA-deficient cancer)3Mc SyndromeOsteochondritis Dissecans
05

Safety considerations

Possible off-target toxicity from DNA repair modulationPotential impact on normal tissue nucleotide metabolism
06

Interacting drugs

Poly(ADP-ribose) polymerase (PARP) inhibitors (synergy via pathway modulation)[1][5]

1 more in the full profile.

07

Biomarkers

DNPH1 expression (for cancer resistance to PARP inhibitors)[1][5]5-hydroxymethyl-dUMP levels (for efficacy monitoring and DNA repair pathway activity)[1]

Beyond the preview

Go deeper on 2'-Deoxynucleoside 5'-phosphate N-hydrolase 1 (DNPH1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2'-Deoxynucleoside 5'-phosphate N-hydrolase 1 (DNPH1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call